Lupin Announces the Approval of Dapagliflozin Tablets in the United States

Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Dapagliflozin Tablets, 5 mg and 10 mg.

The U.S. FDA has approved Lupin's Dapagliflozin Tablets, 5 mg and 10 mg, as bioequivalent to Farxiga® for the indications in the approved labeling.

Shares of Lupin Limited was last trading in BSE at Rs. 2296.60 as compared to the previous close of Rs. 2277.90. The total number of shares traded during the day was 7961 in over 874 trades.

The stock hit an intraday high of Rs. 2309.90 and intraday low of 2247.65. The net turnover during the day was Rs. 18168280.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 Pharmaceuticals USFDA Approval ANDA DapagliflozinTablets